• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lenalidomide may boost prognosis in diffuse large B-cell lymphoma

byMonica ParksandDavid Wang
August 22, 2014
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The addition of lenalidomide to standard R-CHOP chemotherapy reduced the negative prognostic impact of non-GCB phenotype in diffuse large B-cell lymphoma (DLBCL) progression-free and overall survival.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Therapy for diffuse large B-cell lymphoma (DLBCL) has advanced in recent years with the introduction of dose-intensified cytotoxic therapies as well as rituximab. There are two major subtypes of DLBCL: germinal center B-cell-like (GCB) and activated B-cell-like (ABC) or non-germinal center B-cell (non-GCB). Patients with the latter genotype have significantly worse outcomes on the standard chemotherapy combination of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) therapy. The purpose of this study was to further evaluate the effect of adding lenalidomide to R-CHOP (R2CHOP) on survival outcomes in DLBCL. At the conclusion of this phase II clinical trial, the authors found that 24 month progression-free and overall survival did not differ significantly between GCB and non-GCB patients on R2CHOP., indicating a potential benefit of lenalidomide. The results of this trial demonstrate the potential a benefit of R2CHOP in the non-GCB phenotype; however, the trial had a small sample size of patients and additional clinical trials are recommended to validate these results.

Click to read the study in JCO

Relevant Reading: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with Diffuse Large-B-Cell Lymphoma

In-Depth [open-labeled clinical trial]: This phase II clinical trial included 64 patients with diffuse large B-cell lymphoma (DLBCL). Patients received lenalidomide daily for the first 10 days of standard dose R-CHOP for six cycles. Tumor immunohistochemistry was used to determined DLBCL molecular subtype to classify germinal center B-cell (GCB) versus non-GCB. The study authors selected 87 control patients with DLBCL treated with conventional R-CHOP alone from the Mayo Clinic Lymphoma Database. Overall, 98% of patients on R2CHOP achieved complete response to treatment. Event-free and overall survival at 2 years was 59% (95% CI: 48-74%) and 78% (95% CI: 68-90%), respectively. In R-CHOP only patients, progression-free and overall survival were 28% versus 64% (p < 0.001) and 46% versus 78% (p <0.001) in non-GCB versus GCB DLBCL. In R2CHOP patients, there was no difference in 2 year PFS or OS (p = 0.83 and p = 0.61) based on GCB status.

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Image: PD 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: B-cell lymphomalenalidomideprednisonerituximab
Previous Post

Bedaquiline efficacious in treating multidrug resistant tuberculosis: phase 2 trial

Next Post

New method may predict response to chemotherapy for lung cancer

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
#VisualAbstract Oral azacitidine (CC-486) plus R-CHOP shows an acceptable safety profile in untreated diffuse large B-cell lymphoma
StudyGraphics

#VisualAbstract Oral azacitidine (CC-486) plus R-CHOP shows an acceptable safety profile in untreated diffuse large B-cell lymphoma

March 3, 2022
Next Post
Afatinib shows increased progression-free survival in non-small-cell lung cancer

New method may predict response to chemotherapy for lung cancer

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

ADHD stimulant treatment associated with changes in BMI trajectory

Association of obesity and dementia varies with age

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.